Clinical trial · Observational

Study of Serum Tumor Markers of HBV Associated HCC

NCT05825196CI-TRIAL-00065879unknownClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

In this study, the investigators will detect the expression of four potential HBV-related HCC biomarkers: PGIR,FAM3C,LAMB1 and SDC4 in tumor tissues and peripheral blood, to explore the specific molecular markers for the early diagnosis of HBV-related HCC.

Conditions

Conditions (1)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
HCC	—	UNRESOLVED	—

Interventions

Interventions (1)

Intervention	Type	Mapped drug	Match
tumor tissue and blood tests	Diagnostic Test	—	UNRESOLVED

Design

Arms and outcomes

Arms (3)

label
HBV-associated HCC group
description
The patient was finally diagnosed with HBV-related HCC by examination and imaging examination, and the clinicopathologic data were complete.
interventionNames
1. Diagnostic Test: tumor tissue and blood tests
label
negative control group
description
HBV positive but not HCC
interventionNames
1. Diagnostic Test: tumor tissue and blood tests
label
Healthy control group
description
Healthy crowd
interventionNames
1. Diagnostic Test: tumor tissue and blood tests

Primary outcomes (1)

Eligibility

Eligibility (as posted)

Sex: All
Minimum age: 18 Years
Maximum age: 80 Years

Show eligibility criteria text

Inclusion Criteria:

* No local or systemic treatment was performed before surgery. The patients were finally diagnosed with HBV-related HCC by examination and imaging examination, and the clinicopathologic data were complete.

Exclusion Criteria:

* Patients with benign liver diseases, such as hepatic cysts and hepatic hemangiomas, or have tumors other than HBV-related HCC.

References

Publications (0)

Data not yet available

No reference posted for this study.